Literature DB >> 3899004

Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes.

T Tadakuma, N Ikewaki, T Yasuda, M Tsutsumi, S Saito, K Saito.   

Abstract

Liposome-entrapped streptomycin (SM) was compared with free SM for therapeutic efficacy against experimental salmonellosis in mice. All of the mice infected with the virulent strain of Salmonella enteritidis 116-54 died between days 5 and 7, and a dose of 20 mg of free SM per kg administered 24 h after the bacterial inoculation did not prolong the survival. In contrast, the same dose of SM entrapped in liposomes prolonged paralleled the dose in the liposomes, and a dose as low as 1.2 mg of SM per kg in liposomes prolonged the survival. The advantage of using liposomes was more pronounced when a larger dose of SM was employed. The liposome-entrapped drug was less toxic than the free drug. A dose of 80 mg of free SM per kg caused convulsions, but the same dose entrapped in liposomes caused no side effects. Furthermore, two doses of liposome-entrapped SM further enhanced the therapeutic effect. The efficacy of the liposome-entrapped drug was still observed in mice infected with a large inoculum of S. enteritidis. A tissue distribution study on SM in various organs demonstrated that liposomal SM was selectively delivered to the spleen and liver with concentrations in these those in mice receiving the free drug. The prolongation of survival was due to suppression of the multiplication of S. enteritidis as demonstrated by viable cell counts in the spleens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899004      PMCID: PMC176303          DOI: 10.1128/AAC.28.1.28

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Antileishmanial activity of antimonials entrapped in liposomes.

Authors:  R R New; M L Chance; S C Thomas; W Peters
Journal:  Nature       Date:  1978-03-02       Impact factor: 49.962

2.  Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs.

Authors:  C R Alving; E A Steck; W L Chapman; V B Waits; L D Hendricks; G M Swartz; W L Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Morphological observations on the cellular and subcellular destination of intravenously administered liposomes.

Authors:  A W Segal; E J Wills; J E Richmond; G Slavin; C D Black; G Gregoriadis
Journal:  Br J Exp Pathol       Date:  1974-08

4.  Drug entrapment in liposomes.

Authors:  G Gregoriadis
Journal:  FEBS Lett       Date:  1973-11-01       Impact factor: 4.124

5.  Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats.

Authors:  G Gregoriadis; B E Ryman
Journal:  Biochem J       Date:  1972-08       Impact factor: 3.857

6.  Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function.

Authors:  B Holmes; A R Page; R A Good
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

7.  Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.

Authors:  S G Reed; M Barral-Netto; J A Inverso
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

8.  Sporozoite-induced malaria: therapeutic effects of glycolipids in liposomes.

Authors:  C R Alving; I Schneider; G M Swartz; E A Steck
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

9.  Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal.

Authors:  Y E Rahman; B J Wright
Journal:  J Cell Biol       Date:  1975-04       Impact factor: 10.539

  9 in total
  16 in total

1.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors:  S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 2.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

3.  Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.

Authors:  Veronica Gruppo; Christine M Johnson; Karen S Marietta; Hataichanok Scherman; Erin E Zink; Dean C Crick; Linda B Adams; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 4.  Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; P M Melissen; W van Vianen; E W van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 5.  Liposomes and nanoparticles in the treatment of intracellular bacterial infections.

Authors:  P Couvreur; E Fattal; A Andremont
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

6.  Design and evaluation of liposomal formulation of pilocarpine nitrate.

Authors:  S Rathod; S G Deshpande
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

Review 7.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.

Authors:  R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice.

Authors:  H Saito; H Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Infection       Date:  1988       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.